Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Merck

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,571,839

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,571,839
Title: D-aspartic acid .beta.-hydroxamate for the treatment of viral infections and tumors
Abstract:Beta-hydroxamate D-aspartic acid as a medicine, in particular for treating infectious diseases caused by retroviruses, especially those that cause AIDS, as well as for treating tumors.
Inventor(s): Vila; Jorge (Irigny, FR), Thomasset; Nicole (Villeurbanne, FR), Hamedi Sangsari; Farid (Lyons, FR), Grange; Jacques (Oullins, FR)
Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR)
Application Number:08/034,399
Patent Claims:1. A method of treating a patient, comprising administering to said patient an independently therapeutically effective amount of DAH, wherein said patient has HIV or FLV viral infection and said DAH is administered in an amount independently effective to inhibit viral replication associated with said viral infection without administering L-asparaginase to said patient.

2. The method according to claim 1, wherein said viral infection is HIV infection.

3. The method according to claim 1, wherein said administering comprises orally administering.

4. The method according to claim 1, wherein said administering comprises parenterally administering.

5. The method according to claim 4, further comprising dissolving a lyophilized powder of said DAH in a physiologic solution prior to administering the DAH.

6. A method of treating a patient, comprising administering DAH to said patient in an amount of at least about 10 g/day without administering L-asparaginase to said patient, wherein said patient has HIV or FLV viral infection.

7. The method according to claim 6, wherein said viral infection is HIV infection.

8. A method of treating a patient, comprising orally administering DAH to said patient, wherein said patient has HIV or FLV viral infection and said DAH is administered in an amount effective to inhibit viral replication associated with said viral infection without administering L-asparaginase to said patient.

9. The method according to claim 8, wherein said viral infection is HIV infection.

10. The method according to claim 8, wherein said DAH is administered in an amount of at least 10 g/day.

11. A method of treating a patient comprising administering to said patient a composition consisting essentially of a therapeutically effective amount of DAH and a carrier, wherein said patient has HIV or FLV viral infection and said DAH is administered in an amount independently effective to inhibit viral replication associated with said viral infection.

12. The method according to claim 11, wherein said viral infection is HIV infection.

13. A pharmaceutical composition comprising an effective amount of DAH and at least one pharmacodynamically active ingredient but not L-asparaginase.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France89 05744Apr 28, 1989

Details for Patent 5,571,839

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR) 2013-11-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Dow
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.